MEDS VS BCEL Stock Comparison

Performance

MEDS
10/100

MEDS returned -41.09% in the last 12 months. Based on SPY's performance of -13.95%, its performance is below average giving it a score of 10 of 100.

BCEL
10/100

BCEL returned -86.82% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

MEDS
36/100

MEDS receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

BCEL
10/100

BCEL receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

MEDS
10/100

MEDS has missed earnings 9 times in the last 20 quarters.

BCEL
10/100

BCEL has missed earnings 7 times in the last 20 quarters.

Profit

MEDS
22/100

Out of the last 20 quarters, MEDS has had 6 profitable quarters and has increased their profits year over year on 2 of them.

BCEL
10/100

Out of the last 20 quarters, BCEL has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

MEDS
52/100

MEDS has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

BCEL
35/100

BCEL has had a lower than average amount of volatility over the last 12 months giving it a score of 34 of 100.

Sentiment

MEDS

"Sentiment" not found for MEDS

BCEL
67/100

BCEL had a bullish sentiment score of 67.43% across Twitter and StockTwits over the last 12 months. It had an average of 41.47 posts, 16.18 comments, and 61.00 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

TRxADE HEALTH, Inc. Common Stock Summary

Nasdaq / MEDS

Healthcare

Medical - Pharmaceuticals

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.

Atreca, Inc. Class A Common Stock Summary

Nasdaq / BCEL

Healthcare

Biotechnology

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Power up your portfolio